SureTrader SureTrader SureTrader
Home > Boards > US Listed > Cannabis >

Zynerba Pharmaceuticals (ZYNE)

ZYNE RSS Feed
Add ZYNE Price Alert      Hide Sticky   Hide Intro
Moderator: djmurdock
Search This Board:
Last Post: 1/19/2017 8:58:49 PM - Followers: 43 - Board type: Free - Posts Today: 0


Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Investor Relations

Corporate Profile

Zynerba (NASDAQ: ZYNE) is pioneering the development of patent-protected, next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its two lead product candidates in development include ZYN002 and ZYN001, which are being evaluated in five indications. ZYN002 is the first and only synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In June 2016, the company initiated the STAR 1 Phase 2 clinical trial in refractory epilepsy patients and in August 2016, initiated the STOP Phase 2 clinical trial in patients with osteoarthritis of the knee. A Phase 2 clinical trial in patients with Fragile X syndrome will be initiated in the second half of 2016. 

ZYN001, a prodrug of THC that enables transdermal delivery through the skin and circulatory system via a patch, is in preclinical development. A Phase 1 clinical trial is planned in the first half of 2017.

In August 2015, Zynerba completed an initial public offering, raising net proceeds of $42.1 million. As of June 30, 2016, cash and cash equivalents totaled $32.1 million, which is projected to fund five Phase 2 clinical trials through 2017.





Zynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol "ZYNE" on August 5, 2015.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. This offering is being made only by means of a prospectus.



Extremely low float:

Fundamentals

A table providing the fundamentals of the stock
EPS (TTM) 9/30/2016 | -2.47
P/E Ratio 9/30/2016 | --
Market Cap Micro Cap | 146M
Shares Outstanding 9.95M
Float 7.2M

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ZYNE
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ZYNE News: Current Report Filing (8-k) 01/19/2017 03:27:10 PM
ZYNE News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 01/19/2017 03:10:14 PM
ZYNE News: Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock 01/19/2017 09:16:02 AM
ZYNE News: Current Report Filing (8-k) 01/18/2017 04:36:29 PM
ZYNE News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 01/18/2017 04:19:06 PM
PostSubject
#326  Sticky Note Slideshow for new investors djmurdock 12/17/16 05:09:50 PM
#425   It's good timing. The company couldn't have planned WolfOfGrnStreet 01/19/17 08:58:49 PM
#424   Notice timing day before Trump takes office.....Better to eskay1954 01/19/17 04:26:02 PM
#423   Well today sucked. Frustrating because they kept saying djmurdock 01/19/17 04:12:14 PM
#422   Zynerba Pharmaceuticals, Inc. (the “ Company ”) is a surfer 01/19/17 07:54:25 AM
#421   Looks like a correction for today. a surfer 01/19/17 07:54:24 AM
#420   Yes sir! It will be like GWPH last WolfOfGrnStreet 01/18/17 09:41:14 PM
#419   Although GW has a longer history and actually djmurdock 01/18/17 05:27:04 PM
#418   Nice POP today. This stock has way too WolfOfGrnStreet 01/18/17 04:43:45 PM
#417   I'm assuming this non news pop is due djmurdock 01/18/17 03:11:17 PM
#416   $ZYNE$ mega potential. Added more today to my 11's. surfgreen 01/18/17 01:23:14 PM
#415   WHAMMO! Nice 15% so far. 22.59 a surfer 01/18/17 12:51:12 PM
#414   I definitely think this will be over $35 djmurdock 01/18/17 01:28:23 AM
#413   End of 2017 is what I'm looking at! WolfOfGrnStreet 01/17/17 10:38:16 PM
#412   Looks like another popping week possible! Take out a surfer 01/17/17 09:26:21 PM
#411   It would be nice if daytraders would let djmurdock 01/10/17 12:27:08 PM
#410   Nice SA write up, showing a great new djmurdock 01/08/17 02:51:24 PM
#409   I think that 22 is very realistic this week devilmafia 01/08/17 02:43:03 PM
#408   I think we will end the week above djmurdock 01/08/17 02:29:13 PM
#407   http://seekingalpha.com/article/4035064-zynerba-thesis-continues-play-management djmurdock 01/08/17 02:14:56 PM
#406   They will be great in the United States WolfOfGrnStreet 01/07/17 09:25:14 PM
#405   It will! That my opinion and my fact lol WolfOfGrnStreet 01/07/17 09:23:22 PM
#404   Great presentation. I'm in SF, didn't know this djmurdock 01/07/17 02:30:35 PM
#403   8k http://ir.zynerba.com/phoenix.zhtml?c=253915&p=irol-sec eskay1954 01/07/17 01:06:53 PM
#402   I agree. I think being based in the djmurdock 01/06/17 02:54:26 AM
#401   Plant based would be much better. Hopefully Zynerba AUDACIOUSWON 01/06/17 12:09:15 AM
#400   Lol...was thinking the same! Let's see if a surfer 01/05/17 11:56:32 PM
#399   Synthetic will be much easier to get FDA djmurdock 01/05/17 11:25:06 PM
#398   Agreed. Idiot. Synthetic CBD is great for pharma TinyGreenSprout 01/05/17 10:35:22 PM
#397   You're an idiot WolfOfGrnStreet 01/05/17 09:23:58 PM
#396   Synthetic CBD? That's just sad. AUDACIOUSWON 01/05/17 09:13:12 PM
#395   Frustrating how we keep opening so high, then djmurdock 01/05/17 05:34:35 PM
#394   Should be a fabulous day today!!!!! Go Zynerba stocky101 01/05/17 09:14:56 AM
#393   Thumbs up WolfOfGrnStreet 01/04/17 10:31:21 PM
#392   Soon to catch GWPH. Could see $30 this month. biotechnician 01/04/17 07:50:29 PM
#391   They will have 3 Phase 2 trial results djmurdock 01/04/17 06:18:12 PM
#390   Wonderful devilmafia 01/04/17 04:35:51 PM
#389   I believe three drugs are in phase 2 stocky101 01/04/17 04:20:40 PM
#388   Any idea how long Phase 2 might take ? devilmafia 01/04/17 04:18:45 PM
#387   Once these studies pass Phase 2, could see stocky101 01/04/17 03:52:01 PM
#386   It could be a end of day bounce stocky101 01/04/17 03:24:29 PM
#385   Load that boat baby stocky101 01/04/17 03:08:28 PM
#384   It's going to get so much better here, stocky101 01/04/17 03:08:18 PM
#383   It will continue , not even near done yet stocky101 01/04/17 02:42:58 PM
#382   We will in due time. First we need CoachMarc 01/04/17 01:40:43 PM
#381   I agree, we should see 25-30 bucks before devilmafia 01/04/17 01:05:30 PM
#380   I think this will drop back to around CoachMarc 01/04/17 12:48:10 PM
#379   WHOA EOM eskay1954 01/04/17 12:00:55 PM
#378   It's heated up for sure! GLTA! WolfOfGrnStreet 01/04/17 11:37:42 AM
#377   $20 plus coming!! Possible today!! 19.59!!! a surfer 01/04/17 11:36:59 AM
#376   Haven't sold yet. In at 7. See you WolfOfGrnStreet 01/03/17 09:47:01 PM
PostSubject